Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Health...(TDAmargins by the end of fiscal year 200...),Health

Date:2/7/2008

TDA margins by the end of fiscal year 2008 -- a goal that, based on comments made by management during the Company's fourth quarter conference call held on December 11, 2007, the Company appears on track to accomplishing. On this call, Rick Slager, VistaCare's CEO, lauded the Company's progress, specifically citing the Company's reduced headcount and the realization of $17 million of the $29 million annualized net benefits targeted in the Restructuring. Mr. Slager further noted "the trends continue to be positive" and that the benefits of the Restructuring "will take several quarters to be fully realized."

Given VistaCare's current progress and positive outlook regarding the Restructuring, Accipiter believes the market would continue to recognize these results over the next several quarters and reward the Company's stockholders with a stock price far in excess of the Purchase Price. At the very least, we believe the 21% restructuring discount applied by RA Capital was too high and harmed stockholders.

Based on our own calculations and the Company's progress regarding the Restructuring, we believe that VistaCare should conservatively be valued at $11.50 per share. First, we estimate that VistaCare will achieve calendar year 2009 revenues of $250 million based on the fourth quarter of fiscal year 2007 revenue run-rate of $245 million, less annualized revenues of $10 million due to site closures occurring during and after the fourth quarter. With $235 million in revenue as a base, we assume a 3% revenue growth per year, primarily due to market basket updates and slight ADC growth. Therefore, using VistaCare's own 10% EBITDA margin goal, we believe 2009 EBITDA should approach $25 million. Additionally, we note that VistaCare's competitors, Chemed Corporation and Odyssey, trade at 7.9x and 6.4x projected 2009 EBITDA, respectively. Applying the mid-point of that range, or a 7.2x EBITDA multiple, to our estimate of VistaCare's 2009 EBITDA yields, we calculate
'/>"/>

SOURCE Accipiter Capital Management Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Rural/Metro Board of Directors Meets With Accipiter Capital Management
2. Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference
3. Treatment capitalizes on unique qualities of radioisotope to prolong lives of brain tumor patients
4. Capital BlueCross CEO Says Meaningful Statewide Competition Must Be Key Criteria in Pennsylvanias Review of Proposed Highmark-IBC Merger
5. Asthma Foundation Announces 2008 Asthma Capitals, Knoxville on Top Again
6. NovaVision to be Featured at 2008 Florida Venture Capital Conference
7. Health Capital Group Warns of Fallout to Hospitals From the Subprime Mortgage Crisis and Urges Hospitals to Immediately Reassess Existing Debt Structures and Capital Financing Plans
8. Huron Capital Caps Strong Year With Five Acquisitions In 4Q07
9. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Security Capital Assurance Ltd.
10. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
11. Mayo Clinic Proceedings provides forum for debate about capital punishment